Molecularly targeted therapies
|
MDMX-p53 response [3,25,26],
spleen tyrosine kinase (SYK) inhibitors [3,28,29], histone deacetylase (HDAC) inhibitors [3,28,33],
CEP1347 (small-molecule kinase inhibitor) [23]
|
Tubulin Modifying molecules
|
Paclitaxel (PTX) [44]
|
Immunotherapy
|
CAR-T cell therapy [53]
Signal transducer CD24 [59]
Nucleolin (NCL) protein [61,62]
|
High mobility group A (HMGA) protein
|
HMGA aptamer (NCLAb–HMGAap) [68,69]
|
Vitamin D analogs
|
Calcitriol [71,79,80]
|
Angiogenesis inhabitation
|
Celastrol nanomicelles (CNMs) [87]
Ribavirin [20]
|
Neurotransmitter pathway disrupting
|
Transfection of AP-2α and AP-2β expression into Rb cells to induces apoptosis [98]
|
Arsenic Trioxide
|
Arsenic trioxide (white arsenic or As2O3; ATO) [18]
|
EDL-155
|
an isoquinoline derivative [102]
|
Gene therapy
|
HSV- TK / GCV(Herpes Simplex Virus-Tyrosine Kinase / Ganciclovir) [19,104]
Oncolytic adenovirusVCN-01 [106]
|
Local drug-delivery systems
|
Poly lactic-co-glycolic acid (PLGA) [117,118]
Gold-based nanoparticles [126,127]
Dendrimer [133]
|
New hydrogel implant
|
Local drug delivery [134]
|
Non- coding RNAs (ncRNAs)
|
lncRNAs [139-151]
miRNAs [158-161]
|
Aqueous humor markers
|
circulating tumor cell (CTC) and cfDNA-based fluid biopsies [171,172]
|
Exosomes
|
nanoparticles derived from cell membranes containing RNA, microRNA, lipids and proteins [175]
|
|
MLN4924 (Pevonedistat)
|
Pevonedistat, a neddylation inhibitor [180] |
